For years, the United States has paid some of the highest medicine prices in the world, while many European countries have relied on centralized negotiations and public health systems to secure lower costs. Former President Donald Trump sought to challenge that imbalance through a policy concept often described as “most-favored nation” pricing – an approach designed to ensure that Americans would not pay more for prescription medicines than patients in wealthy peer countries. While the policy was framed as relief for U.S. consumers, its ripple effects have been felt far beyond Washington. Across Europe, governments, regulators, insurers, and pharmaceutical companies are now navigating a new period of uncertainty. The central question is no longer whether the United States wants lower prices, but whether Europe will be forced to pay more.
A Global Pricing Puzzle
Drug pricing has always been one of the least transparent areas of global healthcare. Publicly available list prices often differ sharply from the actual prices paid after rebates, discounts, confidential agreements, and performance-based contracts. This is true in both the United States and Europe, though the systems differ significantly. In America, private insurers, pharmacy benefit managers, and manufacturers negotiate behind closed doors. In Europe, ministries of health or national insurance bodies often negotiate directly with drugmakers, using cost-effectiveness reviews and budget impact assessments to justify final reimbursement decisions.
As a result, no one outside these negotiations can easily determine the “real” price of a medicine. This creates a major challenge for any policy based on international price comparisons. If discounts remain secret, reference pricing systems may rely on numbers that do not reflect reality. Trump’s proposal attempted to link U.S. prices to those paid in countries such as Germany, France, and the United Kingdom. Yet experts have questioned how such a system can function when net prices remain confidential and product launches often occur in the U.S. before Europe.
Europe Under New Pressure
Even without full implementation of American reforms, the political message from Washington has been clear: Europe should contribute more to global pharmaceutical revenues.
That argument has been welcomed by many pharmaceutical executives, who have long maintained that European governments suppress medicine prices to unsustainable levels. According to industry leaders, lower revenues in Europe reduce incentives for research investment, clinical trials, manufacturing expansion, and innovation across the continent.
Executives from major companies including AstraZeneca, Roche, and Novartis have publicly suggested that Europe risks losing strategic relevance if it continues to insist on aggressive price controls while the U.S. and Asia offer stronger commercial returns. Some companies have gone further, warning that future medicines may launch later in Europe – or not at all – if pricing expectations are not met.
Governments Face a Difficult Choice
European governments are unlikely to accept price increases without resistance. Most healthcare systems across the continent are publicly funded and already under significant fiscal strain. Aging populations, rising rates of chronic disease, staff shortages, and inflation have placed enormous pressure on national health budgets.
At the same time, many countries are increasing defense spending and responding to broader economic uncertainty. In this environment, allocating billions more to medicines is politically difficult. Health authorities also argue that they are not opposed to paying high prices when treatments deliver transformative value. Gene therapies, breakthrough cancer medicines, and treatments for rare diseases can secure substantial reimbursement if evidence supports their benefit.
The real conflict arises when manufacturers demand premium prices for medicines offering only modest improvements over existing alternatives.
The Role of Health Technology Assessment
One of Europe’s strongest tools in price negotiations is Health Technology Assessment (HTA). Through HTA, authorities evaluate whether a new medicine meaningfully improves outcomes compared with current standards of care, and whether its price represents value for money.
If manufacturers increase list prices dramatically, they may face a new problem: their products could fail cost-effectiveness tests. In that scenario, higher asking prices may actually delay access rather than improve revenues. This creates a paradox for the pharmaceutical industry. While companies want Europe to pay more, excessively aggressive pricing strategies could backfire by preventing reimbursement approvals altogether.
Patients Caught in the Middle
For patients, the consequences of these disputes can be serious. When negotiations fail, access to medicines may be delayed for months or years. This problem is especially acute in smaller or lower-income European countries, where budgets are tighter and bargaining power is weaker. Some innovative medicines reach Germany or France relatively quickly but arrive much later in Central or Eastern Europe. If pricing tensions intensify, those inequalities could widen further.
There is also concern that companies may prioritize launches in markets willing to pay premium prices, leaving other countries waiting indefinitely.
The United Kingdom as a Test Case
The United Kingdom has emerged as an early example of this evolving dynamic. In late negotiations with the United States, Britain reportedly agreed to increase spending on medicines while reforming certain financial mechanisms affecting pharmaceutical companies.
The details remain under discussion, but the message was significant: one major European market signaled willingness to reconsider how much it pays for innovation. Whether that becomes a broader continental trend remains uncertain.
What Happens Next?
The future of global drug pricing is far from settled. Trump’s campaign reignited a debate that extends beyond politics into economics, industrial strategy, and public health. Europe must now balance three competing priorities:
- Keeping medicines affordable for taxpayers
- Maintaining timely patient access to innovation
- Remaining attractive for pharmaceutical investment
Meanwhile, the United States continues searching for ways to lower domestic costs without reducing innovation incentives. The likely outcome is not a dramatic overnight shift, but gradual renegotiation. Some European countries may spend more on selected high-value therapies. Others may harden reimbursement rules. Companies may alter launch strategies market by market.
Comments